News >

Emerging Biomarkers for Targeted Agents Show Promise in NSCLC

Jessica Hergert
Published: Tuesday, Sep 17, 2019

Alex A. Adjei, MD, PhD, professor of oncology and pharmacology at Mayo Clinic

Alex A. Adjei, MD, PhD

As advancing technologies and novel agents continue to expand treatment strategies in non–small cell lung cancer (NSCLC), the quest to develop more effective therapies targeting NTRK, RET, MET, BRAF, and HER2 is underway, said Alex A. Adjei, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication